111 related articles for article (PubMed ID: 14987801)
1. ABL-fusion oncoproteins activate multi-pathway of DNA repair: role in drug resistance?
Majsterek I; Slupianek A; Hoser G; Skórski T; Blasiak J
Biochimie; 2004 Jan; 86(1):53-65. PubMed ID: 14987801
[TBL] [Abstract][Full Text] [Related]
2. Does the bcr/abl-mediated increase in the efficacy of DNA repair play a role in the drug resistance of cancer cells?
Majsterek I; Blasiak J; Mlynarski W; Hoser G; Skórski T
Cell Biol Int; 2002; 26(4):363-70. PubMed ID: 11991666
[TBL] [Abstract][Full Text] [Related]
3. TEL-fusion oncogenic tyrosine kinases determine leukemic cells response to idarubicin.
Majsterek I; Slupianek A; Blasiak J
Anticancer Drugs; 2003 Sep; 14(8):625-31. PubMed ID: 14501384
[TBL] [Abstract][Full Text] [Related]
4. Comparative study of DNA damage, cell cycle and apoptosis in human K562 and CCRF-CEM leukemia cells: role of BCR/ABL in therapeutic resistance.
Pytel D; Wysocki T; Majsterek I
Comp Biochem Physiol C Toxicol Pharmacol; 2006 Sep; 144(1):85-92. PubMed ID: 16904383
[TBL] [Abstract][Full Text] [Related]
5. Imatinib mesylate (STI571) abrogates the resistance to doxorubicin in human K562 chronic myeloid leukemia cells by inhibition of BCR/ABL kinase-mediated DNA repair.
Majsterek I; Sliwinski T; Poplawski T; Pytel D; Kowalski M; Slupianek A; Skorski T; Blasiak J
Mutat Res; 2006 Jan; 603(1):74-82. PubMed ID: 16388976
[TBL] [Abstract][Full Text] [Related]
6. Fusion oncogenic tyrosine kinases alter DNA damage and repair after genotoxic treatment: role in drug resistance?
Hoser G; Majsterek I; Romana DL; Slupianek A; Blasiak J; Skorski T
Leuk Res; 2003 Mar; 27(3):267-73. PubMed ID: 12537980
[TBL] [Abstract][Full Text] [Related]
7. TEL/JAK2 tyrosine kinase inhibits DNA repair in the presence of amifostine.
Gloc E; Warszawski M; Młynarski W; Stolarska M; Hoser G; Skorski T; Błasiak J
Acta Biochim Pol; 2002; 49(1):121-8. PubMed ID: 12136932
[TBL] [Abstract][Full Text] [Related]
8. Imatinib (STI571) induces DNA damage in BCR/ABL-expressing leukemic cells but not in normal lymphocytes.
Czechowska A; Poplawski T; Drzewoski J; Blasiak J
Chem Biol Interact; 2005 Apr; 152(2-3):139-50. PubMed ID: 15840387
[TBL] [Abstract][Full Text] [Related]
9. Impact of p210(Bcr-Abl) on ultraviolet C wavelength-induced DNA damage and repair.
Laurent E; Mitchell DL; Estrov Z; Lowery M; Tucker SL; Talpaz M; Kurzrock R
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3722-30. PubMed ID: 14506164
[TBL] [Abstract][Full Text] [Related]
10. BCR/ABL inhibits mismatch repair to protect from apoptosis and induce point mutations.
Stoklosa T; Poplawski T; Koptyra M; Nieborowska-Skorska M; Basak G; Slupianek A; Rayevskaya M; Seferynska I; Herrera L; Blasiak J; Skorski T
Cancer Res; 2008 Apr; 68(8):2576-80. PubMed ID: 18413724
[TBL] [Abstract][Full Text] [Related]
11. Interaction of amoxicillin with DNA in human lymphocytes and H. pylori-infected and non-infected gastric mucosa cells.
Arabski M; Kazmierczak P; Wisniewska-Jarosinska M; Poplawski T; Klupinska G; Chojnacki J; Drzewoski J; Blasiak J
Chem Biol Interact; 2005 Feb; 152(1):13-24. PubMed ID: 15766919
[TBL] [Abstract][Full Text] [Related]
12. BCR/ABL regulates response to DNA damage: the role in resistance to genotoxic treatment and in genomic instability.
Skorski T
Oncogene; 2002 Dec; 21(56):8591-604. PubMed ID: 12476306
[TBL] [Abstract][Full Text] [Related]
13. DNA damage and repair in BCR/ABL-expressing cells after combined action of idarubicin, STI571 and amifostine.
Blasiak J; Gloc E; Pertyński T; Drzewoski J
Anticancer Drugs; 2002 Nov; 13(10):1055-60. PubMed ID: 12439339
[TBL] [Abstract][Full Text] [Related]
14. Amifostine can differentially modulate DNA double-strand breaks and apoptosis induced by idarubicin in normal and cancer cells.
Wozniak K; Gloc E; Morawiec Z; Blasiak J
Exp Oncol; 2008 Mar; 30(1):22-8. PubMed ID: 18438337
[TBL] [Abstract][Full Text] [Related]
15. Cisplatin-evoked DNA fragmentation in normal and cancer cells and its modulation by free radical scavengers and the tyrosine kinase inhibitor STI571.
Wozniak K; Czechowska A; Blasiak J
Chem Biol Interact; 2004 Apr; 147(3):309-18. PubMed ID: 15135086
[TBL] [Abstract][Full Text] [Related]
16. Role of p21(WAF1/CIP1) as an attenuator of both proliferative and drug-induced apoptotic signals in BCR-ABL-transformed hematopoietic cells.
Forster K; Obermeier A; Mitina O; Simon N; Warmuth M; Krause G; Hallek M
Ann Hematol; 2008 Mar; 87(3):183-93. PubMed ID: 17960378
[TBL] [Abstract][Full Text] [Related]
17. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
[TBL] [Abstract][Full Text] [Related]
18. FAK silencing inhibits leukemogenesis in BCR/ABL-transformed hematopoietic cells.
Le Y; Xu L; Lu J; Fang J; Nardi V; Chai L; Silberstein LE
Am J Hematol; 2009 May; 84(5):273-8. PubMed ID: 19358301
[TBL] [Abstract][Full Text] [Related]
19. STI571 reduces NER activity in BCR/ABL-expressing cells.
Sliwinski T; Czechowska A; Szemraj J; Morawiec Z; Skorski T; Blasiak J
Mutat Res; 2008 Jul; 654(2):162-7. PubMed ID: 18602021
[TBL] [Abstract][Full Text] [Related]
20. Genotoxicity of idarubicin and its modulation by vitamins C and E and amifostine.
Błasiak J; Gloc E; Woźniak K; Młynarski W; Stolarska M; Skórski T; Majsterek I
Chem Biol Interact; 2002 Apr; 140(1):1-18. PubMed ID: 12044557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
